Navigation Links
A Weight Neutral Oral Antidiabetic Drug Would Earn a 25 Percent Patient Share in the Type 2 Diabetes Drug Market
Date:7/1/2008

Advantages in Efficacy and Safety Will Make Liraglutide the New Clinical

Gold Standard Drug by 2011, According to a New Report from Decision

Resources

WALTHAM, Mass., July 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a weight neutral oral antidiabetic drug would earn a 25 percent patient share in the treatment of type 2 diabetes, according to surveyed primary care physicians. Given the prices set for each of the drug profiles and the size of the type 2 diabetic patient population in 2011, a 25 percent patient share would result in sales of $4.1 billion for an agent fitting the report's Minimal Acceptable drug profile and $8.1 billion for an agent fitting the report's Major Achievement profile.

The new report entitled Type 2 Diabetes: Blockbuster-Bound Januvia Addresses Physicians' Concern over Hypoglycemia also finds that Novo Nordisk's liraglutide will become the new Decision Resources' proprietary clinical gold standard for the treatment of type 2 diabetes by 2011 as surveyed primary care physicians indicate that liraglutide has competitive advantages in terms of efficacy and safety in comparison to the current gold standard, metformin. Although liraglutide has disadvantages in the area of delivery because of its subcutaneous injectable formulation, its positive efficacy and safety attributes offset its disadvantage in delivery.

"Interviewed primary care physicians also state that liraglutide offers a considerable advantage over other current and emerging type 2 diabetes therapies in terms of weight loss," said Donny Wong, Ph.D., principal analyst at Decision Resources. "As a result, we forecast liraglutide to become the clinical gold standard among the agents covered in our analysis."

About the Report

Type 2 Diabetes: Blockbuster-Bound Januvia Addresses Physicians' Concern over Hypoglycemia is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. High Birth Weight Doubles Risk of Rheumatoid Arthritis
2. Weight Watchers Receives Adverse U.K. VAT Ruling
3. Heavy birthweight increases risk of developing rheumatoid arthritis
4. Heavy birthweight babies twice as likely to develop rheumatoid arthritis
5. One Year Later, Millions are Losing Weight with alli(R)
6. Weight gain within the normal range increases risk of chronic kidney disease
7. Big, Well-Balanced Breakfast Aids Weight Loss
8. Minimally-invasive weight loss surgery improves health and morbidly obese teens
9. Weight Loss After Gastric Bypass Is Key to Easing Diabetes
10. A Simple Weight Loss Diet: Scientific, Safe and Basically Free
11. Weight loss after gastric bypass surgery may protect against infection and cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
Breaking Medicine Technology: